Spots Global Cancer Trial Database for stage iv laryngeal squamous cell carcinoma ajcc v7

Every month we try and update this database with for stage iv laryngeal squamous cell carcinoma ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer	NCT01810913	Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha...	Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT01064479	Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Carboplatin Cisplatin Docetaxel Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer	NCT01810913	Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha...	Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT01064479	Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Carboplatin Cisplatin Docetaxel Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: